about
Cell membrane integrity in myotonic dystrophy type 1: implications for therapyCombined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.Effectiveness and cost-effectiveness of a self-management group program to improve social participation in patients with neuromuscular disease and chronic fatigue: protocol of the Energetic study.Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial.Overweight Is an Independent Risk Factor for Reduced Lung Volumes in Myotonic Dystrophy Type 1.Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.Double SMCHD1 variants in FSHD2: the synergistic effect of two SMCHD1 variants on D4Z4 hypomethylation and disease penetrance in FSHD2.Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy.Mutation-specific effects on thin filament length in thin filament myopathy.Monitoring creatine and phosphocreatine by (13)C MR spectroscopic imaging during and after (13)C4 creatine loading: a feasibility study.Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.Genetic defects in the hexosamine and sialic acid biosynthesis pathway.What's in a name? The clinical features of facioscapulohumeral muscular dystrophy.The wrong end of the telescope: neuromuscular mimics of movement disorders (and vice versa).The yield of diagnostic work-up of patients presenting with myalgia, exercise intolerance, or fatigue: A prospective observational study.Integrating clinical and genetic observations in facioscapulohumeral muscular dystrophy.Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It.The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands.Characterization of sarcoplasmic reticulum Ca(2+) ATPase pumps in muscle of patients with myotonic dystrophy and with hypothyroid myopathy.The Dutch patients' perspective on oculopharyngeal muscular dystrophy: A questionnaire study on fatigue, pain and impairments.Cytokine genes as potential biomarkers for muscle weakness in OPMD.Cost-effectiveness of shared medical appointments for neuromuscular patients.Respiratory function in facioscapulohumeral muscular dystrophy 1.Respiratory pattern in a FSHD pediatric population.No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected fibromyalgia syndrome.PGM1 deficiency: Substrate use during exercise and effect of treatment with galactose.Recognizing the tenascin-X deficient type of Ehlers-Danlos syndrome: a cross-sectional study in 17 patients.Bilateral Vestibulopathy Aggravates Balance and Gait Disturbances in Sensory Ataxic Neuropathy, Dysarthria, and OphthalmoparesisDynamic stability during level walking and obstacle crossing in persons with facioscapulohumeral muscular dystrophyGait propulsion in patients with facioscapulohumeral muscular dystrophy and ankle plantarflexor weaknessConsequences of epigenetic derepression in facioscapulohumeral muscular dystrophyGenetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort
P50
Q28544911-E9D15D71-E98B-4500-8BCF-B1DF6EC713AEQ35532209-0DADBC17-919D-4566-A061-DE9619031B81Q35544490-C8EE5BAA-B393-45C6-B6DF-3DE7C9EC2A3CQ35668084-CA64BF36-95B5-45E6-ABE1-73AB69886DABQ35970616-1A550F71-9FE8-4EFC-B063-C32C728750D8Q36105253-82AB85A4-CE85-480D-A493-52FB7934A739Q36424500-46A735A9-BDC1-4852-AA8F-A1AE9D7077CFQ36695869-3336AB52-E691-4549-8BC4-107816114603Q36891155-F3222173-2E01-4C8E-B510-FA83504E5966Q37015525-BC1B5EB9-9EFB-48A7-9D8C-C39ABC978F7FQ37153396-949D2A19-DC14-4B01-AEB8-F7777E89DB68Q38314711-A6138267-1CFC-4DC1-908A-C12C726D2269Q38684317-B54F3BEB-D420-422C-A43A-8F7726F05C93Q38728144-150BC7E9-4F92-47B5-928E-59226D5051CAQ38769259-B8D1C4E0-5A2F-4417-8F67-E91F6BECDCB0Q38771160-4E9366DF-BDB4-46C2-BF0A-C5022E6948F9Q38844133-8915493B-07AA-456F-921F-6A307C2F6240Q38999120-CBEB2D1C-480F-4005-9D1F-D4DCFDAD0B4DQ39486639-69CEC798-C84A-48EC-86CD-D713FA0C4EB5Q39745143-ACD1E70F-33FC-4BA8-A9C3-922F1092045EQ39805605-773BB1E5-5403-4171-99DB-5EAB37D43E6DQ39943862-14BFABA8-2C80-4AD1-9B72-46AB649FA0ABQ40629006-670D508A-D4B4-4642-BC75-CA64F223D2A3Q40723504-528ADDC2-0BB5-4D14-A7F1-8C454B896730Q47917541-0E42BF48-8621-411E-B415-CBC0A9DABFEFQ47950028-C0014323-B605-42EE-9304-99DE0DA54D09Q50903217-980EB980-C60D-46F1-97A2-AEAD7EDA0513Q51140524-F63313D9-4068-46AC-B6B6-1DB92F9EF745Q51539316-64F03466-3AF3-464D-A737-B6FB9421B834Q62671187-DAF6F52C-9315-4AAF-A7A4-49C3A5451341Q85502968-D1141E55-638F-4628-ABBA-C0B9DFF342EEQ86748927-B3A3532A-F245-42F4-93B3-32499A2DDD87Q89839529-C2F1B957-B09E-466F-B0FA-65581F79C586Q92507911-3236FDD2-732A-490D-8AC0-D48087E5BFB4
P50
description
researcher, ORCID id # 0000-0001-9867-9047
@en
wetenschapper
@nl
name
Baziel G van Engelen
@ast
Baziel G van Engelen
@en
Baziel G van Engelen
@nl
type
label
Baziel G van Engelen
@ast
Baziel G van Engelen
@en
Baziel G van Engelen
@nl
prefLabel
Baziel G van Engelen
@ast
Baziel G van Engelen
@en
Baziel G van Engelen
@nl
P106
P31
P496
0000-0001-9867-9047